RSS Feeds
Search

Out-licensing

The TDS Technology

Transdermal Delivery Solutions Corp
Readily formulated, rapidly absorbed, broadly applicable liquid transdermal delivery enabling sprayed-on, rubbed-in, rapidly effective products across therapeutic categories. No patch or device required, only a low-cost, readily available metered pump.

Full description

Readily formulated, rapidly absorbed, broadly applicable liquid transdermal delivery enabling sprayed-on, rubbed-in, rapidly effective products across therapeutic categories.  No patch or device required other than a low-cost, readily available metered pump. Peer-reviewed journal publications available.

There is currently no known limit to the molecular weight of compounds deliverable with this system. Formulation is a function of mathematical calculations and proceeds rapidly.  Onset of activity is seconds to minutes after application.  Preliminary proof-of-concept data up to human trials available in several therapeutic categories, including chemotherapeutics, anti-infectives, NSAIDS, pain relievers, caine drugs, CNS active drugs and hormone replacement.

Company has the capability to formulate, perform accelerated and long term stability protocols and scale up to 20 Liter cGMP batches required for CMC dossiers on the compounds.  The company is currently progressing 2 hormone replacement products and two non-steroidal anti-inflammatory drugs and acetaminophen.  Projects pending include Diazepam, Rivastigmine, and Ciprofloxacin.

Development status

Phase III

Patent information

Other patents pending.

Type of business relationship sought

TDSC seeks well-positioned, market dominant partners, preferably with an investment in brand ever-greening for well-known well characterized APIs.  While the company will consider early-stage partnerships, the technology's value is optimized through internal development.  Company prefers to form and capitalize subsidiary companies with related therapeutic applications likely to be of interest as a unit.  Licenses of individual applications may be considered.  Global partnerships are preferred.

Through its not-for-profit affiliate, Langford Research Institute, collaboration with disease-specific not-for-profits are encouraged. Langford Research is an NIH, FDA and DEA registered facility.

Patent number

U.S. Patent Number 6,444,234, 6,787,152, 7,267,829, European Patent Number 1 094 781 B1

Related reports

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2014 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us